Nasdaq:US$18.99 (+0.58) | HKEX:HK$30.40 (+0.05) | AIM:£3.12 (+0.08)
Search
Announcements
1
2
3456789101112131415
found Documents: 748
Announcements & Press Releases, Regulatory Notice | 13 Jul 2023

HUTCHMED Announces Changes to Board of Directors and Technical Committee
Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee   Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 13, 2023: HUTCHMED (China) Limit
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcement Topics, Regulatory Notice | 13 Jul 2023

List of Directors and Their Roles and Functions
HKEX Announcement (PDF)
Announcement Topics, Oncology / Immunology | 10 Jul 2023

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China
Hong Kong, Shanghai & Florham Park, NJ — Monday, July 10, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I study in China of HMPL-415, an investigational novel selective a
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Jul 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Jun 2023

Blocklisting Six Monthly Return
Hong Kong, Shanghai, & Florham Park, NJ — Thursday, June 29, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: 1. Name of applicant:
Read More
LSE RNS AnnouncementHKEX Announcement
Announcements & Press Releases, Group | 26 Jun 2023

HUTCHMED to Announce 2023 Half-Year Financial Results
Hong Kong, Shanghai & Florham Park, NJ — Monday, June 26, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2023 on Monday, July 31, 2023 at 7:00
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 16 Jun 2023

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 15 Jun 2023

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
— Application Includes Data from Phase III FRESCO-2 and FRESCO Clinical Trials, which Demonstrated Superiority of Fruquintinib Plus Best Supportive Care (“BSC”) vs. Placebo plus BSC for Adult Patients with Previously Treated Metastatic Colore
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 9 Jun 2023

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings
Hong Kong, Shanghai & Florham Park, NJ — Friday, June 9, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data related to two novel investigational hematological malig
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 6 Jun 2023

Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, June 6, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on June 5, 2023, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Jun 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 May 2023

Total Voting Rights
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 26 May 2023

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO-2 and FRESCO clinical trials —   OSAKA, Japan, CAMBRIDGE, Massachusetts, HONG KONG, SHANGHAI &
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 26 May 2023

HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
Hong Kong, Shanghai & Florham Park, NJ — Thursday, May 25, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data related to HUTCHMED’s novel investigational cancer therapi
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 17 May 2023

Standard form for notification of major holdings
TR-1: Standard form for notification of major holding   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i ">1a. Identity of the issuer or the underlying iss
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 12 May 2023

List of Directors and Their Roles and Functions
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 12 May 2023

Annual General Meeting held on May 12, 2023 – Poll Results
Hong Kong, Shanghai, & Florham Park, NJ: Friday, May 12, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and special resolution put to its Annual Genera
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 12 May 2023

HUTCHMED Announces Board of Directors and Board Committee Membership
Hong Kong, Shanghai & Florham Park, NJ  — Friday, May 12, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) refers to its announcement on May 10, 2023 of the appointment of Professor Solange P
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 10 May 2023

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees
Hong Kong, Shanghai & Florham Park, NJ  — Wednesday, May 10, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that that Professor Solange Peters is appointed as an Independent
Read More
LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 May 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 28 Apr 2023

Total Voting Rights
LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 21 Apr 2023

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Friday, April 21, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on Apr
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 18 Apr 2023

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 18, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that its New Drug Application (“NDA”) for fruquintinib in combination with paclitaxe
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 12 Apr 2023

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, April 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new and updated clinical and non-clinical data related to five HUTCHMED investigation
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Event, Regulatory Notice | 11 Apr 2023

Annual General Meeting 2023
Date: Friday, May 12, 2023 Time: 5:00 pm Hong Kong Time (10:00 am London Time) Location:1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom, Kowloon, Hong Kong  
Read More
Circular - Annual General MeetingForm of ProxyOnline AGM User Guide (PDF)2022 Annual ReportLetter to new registered shareholders and reply formNotification letter to registered holders and request formNotification letter to non-registered holders and request formAnnouncement - Notice of Annual General Meeting2022 Sustainability Report
Announcements & Press Releases, Group | 11 Apr 2023

2022 Annual Report and Notice of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, April 11, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2022 Annual Report together with the Notice of Annual General Meeting and the Form
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)HKEX - Notice of Annual General Meeting
Announcements & Press Releases, Regulatory Notice | 11 Apr 2023

Intended Retirement of Independent Non-executive Director
Hong Kong, Shanghai & Florham Park, NJ  — Tuesday, April 11, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Dr Karen Jean Ferrante has informed the Company that she wou
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 4 Apr 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 4 Apr 2023

HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 4, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has consulted the China National Medical Products Administration (“NMPA”) and reach
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Mar 2023

Total Voting Rights
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 31 Mar 2023

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China — — FRESCO-2 showed fruquintinib treatment reduced the risk of death by 34% in
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcement Topics, Oncology / Immunology | 14 Mar 2023

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, March 14, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that, further to its announcement on January 23, 2023 and following the completion of
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 13 Mar 2023

HUTCHMED Confirms No Assets Held at Silicon Valley Bank
Hong Kong, Shanghai & Florham Park, NJ — Monday, March 13, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today confirms that it does not have any exposure to Silicon Valley Bank (“SVB”) or Si
Read More
View Press Release (PDF)
Announcement Topics, Regulatory Notice | 8 Mar 2023

Director’s Share Dealing
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 8, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; SEHK:13) has received notifications that Mr Johnny Cheng, Executive Director and Chief Financial
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 6 Mar 2023

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Monday, March 6, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2022 annual results of HUTCHMED on February 28, 2023, the foll
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Mar 2023

Monthly Return
HKEX Announcement (PDF)
Announcement Topics, Regulatory Notice | 28 Feb 2023

Publication of Form 20-F
Hong Kong, Shanghai & Florham Park, NJ: Tuesday, February 28, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today published the Form 20-F for the financial year ended December 31, 2022.  This is available for viewing
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 28 Feb 2023

HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full Year 2022 oncology/immunology revenues driven by sign
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 27 Feb 2023

HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
Hong Kong, Shanghai & Florham Park, NJ — Monday, February 27, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that it has completed patient enrollment of Phase II registration trial of amdizalisib
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Feb 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 31 Jan 2023

HUTCHMED to Announce 2022 Final Results
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 31, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2022 on Tuesday, February 28, 2023 at
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 23 Jan 2023

HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
— HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S., Eur
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 18 Jan 2023

HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, January 18, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Jan 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 3 Jan 2023

HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 3, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that it has completed patient enrollment of ESLIM-01, a pivotal Phase III clinical tria
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Dec 2022

Blocklisting Six Monthly Return
Hong Kong, Shanghai, & Florham Park, NJ — Friday, December 30, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: 1. Name of applican
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 19 Dec 2022

HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
— Company plans to complete rolling submission to the U.S. in the first half of 2023, followed by filings in Europe and Japan — — NDA is supported by global Phase III FRESCO-2 study conducted in the U.S., Europe, Japan and Australia — — F
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Dec 2022

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 15 Nov 2022

HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets   Hong Kong, Shanghai & Florham Park, NJ — Tuesday, November 15, 2022: HUTCHMED (China) Limited (“HUTCHMED”)
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 14 Nov 2022

HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically significant
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
1
2
3456789101112131415